Objectives: The aim of this study was to determine the causes of death among Asian non-valvular atrial fibrillation (AF) patients who were registered in a nationwide AF registry, and to investigate the differences in the causes of death in AF patients compared between those who were taking and not taking oral anticoagulant (OAC).
Methods: The COhort of antithrombotic use and Optimal INR Level in patients with non-valvular Atrial Fibrillation in Thailand (COOL-AF) study enrolled non-valvular AF patients from 27 centers in Thailand during 2014-2017 to create the COOL-AF Thailand registry. Cause of death was classified as cardiovascular (CV) death, non-CV death, or undetermined cause of death. All events were evaluated and verified by an independent adjudication committee.
Results: There was a total of 3,405 patients (mean age: 67.8 years, 41.8% female), and the mean follow-up duration was 31.8±8.7 months. Three hundred and eighty patients (11.2%) died during follow-up. CV death, non-CV death, and undetermined cause accounted for 121 (31.8%), 189 (49.7%), and 70 (18.4%) patients, respectively. Of those with a known cause of death, heart failure (10%), intracranial hemorrhage (ICH; 10%), sudden cardiac death (6.8%), and ischemic stroke (5.8%) were the most often observed causes of death. Concerning non-CV death, infection/sepsis (27.7%), cancer (5.5%), respiratory (5.2%), and major bleeding (4.5%) were the most prevalent causes of death. The use and type of OAC were found to be major determinants of ICH and major bleeding incidence.
Conclusion: Death due to ischemic stroke was responsible for only 4.7% of all deaths in Asian AF patients. Non-CV death, such as infection/sepsis or malignancy, was more far more prevalent than CV death in Asian AF patients. An improved integrated care approach is needed to reduce the prevalence of non-CV death in Asian AF patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977019 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0282455 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials.
Eur J Heart Fail
December 2024
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Aims: The temporal changes in clinical profiles and outcomes of high-risk myocardial infarction survivors enrolled in clinical trials are poorly described. This study compares mortality rates, baseline characteristics, and the prognostic impact of therapies among participants of the VALIANT and PARADISE-MI trials.
Methods And Results: Exclusively VALIANT participants who matched the inclusion criteria of the PARADISE-MI trial were included in the analysis.
Phenotyping patients with chronic obstructive pulmonary disease and heart failure.
ESC Heart Fail
November 2024
Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Aims: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are prevalent comorbidities associated with significant morbidity/mortality. We assessed prevalence of, patient profiles and outcomes associated with COPD across the ejection fraction (EF) spectrum.
Methods: HF patients enrolled in the Swedish HF registry between 2005 and 2021 were considered.
Analysis of the Impact of Inactivated A71 Vaccine on the Incidence of Hand-Foot-Mouth Disease in Pudong New Area, Shanghai.
Vaccines (Basel)
August 2024
Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China.
Article Synopsis
- This study examined the inactivated A71 (EV-A71) vaccination levels and its impact on hand-foot-mouth disease (HFMD) in Pudong New Area, Shanghai, using data from 2016 to 2022.
- Out of 484,056 vaccine doses given, the first dose vaccination rate was 14.03%, while the full vaccination rate was 13.33%, and significant yearly differences were found.
- Despite the low vaccine coverage, HFMD incidence showed a decline post-vaccination, with most cases being caused by non-EV-A71 and non-CV-A16, highlighting the need for new combined vaccines for better protection.
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
J Am Coll Cardiol
October 2024
Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Background: Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk.
Objectives: This study sought to assess the effect of semaglutide 2.4 mg on all-cause death, CV death, and non-CV death, including subcategories of death and death from coronavirus disease-2019 (COVID-19).
Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records.
PLoS One
August 2024
Cardiovascular Center, Territorial Specialistic Department, University Hospital and Health Services of Trieste, Trieste, Italy.
Article Synopsis
- LDL cholesterol is a major focus for preventing cardiovascular events, and Proprotein Convertase Subtilisin-Kexin type 9 inhibitors (PCSK9-i) have become an important treatment to lower LDL levels.
- A recent study aimed to understand how many people qualify for PCSK9-i treatment and how effective it is by analyzing electronic health records from 2017 to 2020.
- Results showed that only 8% of eligible individuals received PCSK9-i, but those treated experienced a significant reduction in the risk of death and hospitalizations compared to those who didn't receive the treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!